IL1β+ macrophages promote intestinal fibrosis in Crohn’s disease by secreting AREG to activate PI16+ fibroblasts
Excessive extracellular matrix deposition is a hallmark of intestinal fibrosis in Crohn’s disease (CD), with fibroblasts playing a central pathogenic role. This study aimed to elucidate how macrophages regulate fibroblast activity and contribute to intestinal fibrosis development in CD. Single-cell RNA sequencing (scRNA-seq) data from the Cleveland and MGH cohorts were integrated to identify IL1β+ macrophages and PI16+ fibroblasts involved in CD-associated fibrosis. Subsequently, above cell–cell interactions were validated by in vitro experiments such as flow cytometry, co-culture assays, ELISA and western blotting. The functional role of amphiregulin (AREG) and its neutralizing antibody AR37 was further assessed in the DSS-induced chronic intestinal fibrosis mice models. PI16+ fibroblasts exhibited the highest ECM score, indicating their prominent role in extracellular matrix production. IL1β+ macrophages showed the highest pro-fibrotic signature score, suggesting strong pro-fibrotic potential. The ligand–receptor analysis revealed AREG–EGFR interactions between IL1β+ macrophages and PI16+ fibroblasts. The scRNA-seq data identified IL1β+ macrophages as the predominant cellular source of pro-fibrotic factor AREG. Moreover, the in-vitro assays revealed that IL1β+ macrophages promoted proliferation and activation of PI16+ fibroblasts by secreting AREG. The animal experiment results revealed that AREG neutralizing antibody AR37 attenuated PI16 + fibroblasts expansion and intestinal fibrosis in DSS-induced chronic fibrosis models. IL1β+ macrophages promote intestinal fibrosis of CD by increasing proliferation and activation of PI16 + fibroblasts via AREG-EGFR signaling. Targeting the AREG-EGFR signaling could disrupt IL1β+ macrophages-PI16+ fibroblasts crosstalk to mitigate intestinal fibrosis progression in CD.
Authors
- Xia He (ORCID: https://orcid.org/0000-0002-7314-1002)
- Guanzhan Liang
- A. Abulimiti
- Chuanyuan Liu
- Ruibin Li (ORCID: https://orcid.org/0000-0001-6471-7658)
- Yi-Le Guo
- Lu Wang (ORCID: https://orcid.org/0000-0002-0073-0666)
- Zhenyu Xian
- Abudumaimaitijiang Tuersun (ORCID: https://orcid.org/0009-0003-1792-4859)
- H.-Q. Xie
- Yimamu Baihetiyaer
- Lei Lian
- Chunbo He
- Yuxi Pan
- Tuo Hu
- Jia Ke
- Tao Ma
- Jing Chen
- Taiwei Mo
- Xiaofeng Wen
Institutions
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Ganzhou People's Hospital (CN)
- Fujian Provincial Hospital (CN)
- First Affiliated Hospital of Jinan University (CN)
- Kashi University (CN)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1186/s12967-026-07969-7
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00